Eisai, Biogen launch rolling BLA for subcutaneous Alzheimer’s therapy Leqembi
After missing their initial target in March 2024, Eisai and Biogen have initiated a rolling BLA for a subcutaneous maintenance formulation of Leqembi, which could offer a more convenient dosing schedule for Alzheimer’s disease patients.